Imatinib Hcs (Imatinib)

Imatinib binds to the ATP‑binding site of the BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing their activation. This blocks downstream signaling that drives cell proliferation and survival, leading to cytostatic and cytotoxic effects on cancer cells while largely sparing normal tissues.

The prescribing physician determines the dose of Imatinib Hcs based on the patient’s specific diagnosis, disease stage, body weight, renal and hepatic function, and any concomitant medications. Dosing is individualized and should follow current clinical guidelines and the prescriber’s clinical judgment.

Safety data for Imatinib in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To request Imatinib Hcs, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib was the first targeted tyrosine‑kinase inhibitor approved for CML and related diseases, offering oral administration and a well‑characterised safety profile. Newer agents such as dasatinib, nilotinib or ponatinib may provide alternative potency or activity against resistant mutations, but choice of therapy depends on disease characteristics, mutation status and individual patient factors.

Imatinib Hcs should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and excessive heat. Do not store in the bathroom or near a kitchen sink to maintain product stability.

Imatinib Hcs is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any dietary considerations to ensure consistent absorption.

Serious adverse events include hepatotoxicity, severe neutropenia, cardiac failure, and pulmonary hypertension. Patients should be monitored regularly for liver enzyme elevations, blood count changes, and signs of cardiac or pulmonary complications, and therapy should be adjusted or discontinued if these events occur.

Imatinib Hcs should be avoided in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with uncontrolled infections, severe hepatic impairment, or pre‑existing cardiac conditions, and it is generally not recommended for pregnant or breastfeeding women without specialist guidance.